Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.
Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.
SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.
Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced that shareholders of both SciSparc and AutoMax Motors Ltd. have approved their proposed merger. The strategic reverse merger will result in SciSparc acquiring 100% of AutoMax's share capital, with SciSparc shareholders retaining 50.01% ownership of the combined company.
AutoMax, a leading parallel vehicle importer in Israel, specializes in importing and distributing electric vehicles from Anhui Jianghuai Automobile Group. SciSparc has already provided financial support to AutoMax through a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025. The merger's completion remains subject to Israeli court approval.
SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced that shareholders have approved its merger with AutoMax Motors, a leading parallel vehicle importer in Israel. The strategic reverse merger will result in SciSparc acquiring 100% of AutoMax's share capital, with SciSparc shareholders retaining 50.01% of the combined company.
The merger represents a significant pivot from SciSparc's pharmaceutical focus to include automotive operations, particularly in electric vehicle distribution. SciSparc has already invested in AutoMax through a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025. The deal's closing remains subject to AutoMax shareholder approval and Israeli court approval.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of an international patent application for their novel combination therapy. The therapy combines Clearmind's MEAI with SciSparc's Palmitoylethanolamide (PEA) to target metabolic syndrome and obesity.
The patent application, published under the European Patent Office, represents one of 13 patent families filed across multiple jurisdictions including the US, Europe, and China. The collaboration aims to address conditions affecting up to one-third of U.S. adults, combining PEA's anti-inflammatory properties with MEAI's pharmacological profile to treat metabolic disorders, mental health conditions, and addictions.
SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, reported significant progress in its proposed reverse merger with AutoMax Motors, Israel's exclusive importer of JAC electric vehicles. The SEC has declared effective the Form F-4 registration statement for the merger on July 21, 2025.
The merger agreement, initially announced in April 2024, will result in SciSparc acquiring 100% of AutoMax's share capital. Special shareholder meetings are scheduled for August 25, 2025 (SciSparc) and August 28, 2025 (AutoMax) to vote on the merger approval. The transaction remains subject to shareholder approvals from both companies and Israeli court approval.
SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel combination therapy using MEAI and PEA compounds, targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
The therapy combines 5-methoxy-2-aminoindane with N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA) to address global health challenges affecting over 890 million people with obesity and 30% of the global adult population with non-alcoholic fatty liver disease (NAFLD). This development expands their existing patent portfolio across multiple jurisdictions.
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders and rare diseases, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received official notification from Nasdaq on July 18, 2025, confirming that its shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days, satisfying Listing Rule 5550(a)(2).
With this achievement, Nasdaq has closed the previous bid price deficiency matter, marking an important milestone for SciSparc's continued listing on the exchange.
SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders, has announced a 1-for-21 reverse share split effective July 3, 2025. The company's outstanding shares will be reduced from 11,225,751 to approximately 534,600 shares, with about 516,727 shares publicly held.
The stock will continue trading under the symbol "SPRC" on the Nasdaq Capital Market with a new CUSIP number M82618121. The reverse split, approved by shareholders in October 2024, will not alter shareholders' ownership percentages except for minor adjustments due to fractional share treatment. All outstanding options and warrants will be proportionally adjusted.
SciSparc Ltd. (SPRC) has announced the publication of a Japanese divisional patent application for a novel pharmaceutical combination. The patent covers an innovative combination of paracetamol and palmitoylethanolamide (PEA) designed to enhance pain and fever relief while requiring lower doses than traditional paracetamol treatments.
The combination aims to provide a safer and more effective treatment option by leveraging PEA's ability to boost the body's endocannabinoid system. This synergistic approach could potentially reduce the risk of liver damage associated with paracetamol while improving therapeutic outcomes for acute, chronic, and neuropathic pain, as well as fever management.
SciSparc Ltd. (SPRC) and Clearmind Medicine Inc. (CMND) announced the publication of a European patent application for their combination therapy targeting cocaine addiction. The treatment combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's Palmitoylethanolamide.
The patent is based on preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their natural reward responses, suggesting its specificity in targeting drug-related compulsions. This European patent application adds to existing applications filed in the U.S. and other global territories.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel treatment targeting eating disorders, including anorexia and bulimia. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA).
The collaboration aims to address the complex neurobiological and psychological aspects of eating disorders, which are among the top ten leading causes of disability in young women. Recent statistics show that eating disorders affect up to 70 million people globally, with prevalence rates increasing from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents.